Medtronic plc (MDT) continues to shine as one of the best high-yield dividend stocks heading into 2025 and beyond. The company recently won an appeal, avoiding a $106.5M patent verdict, and has appointed a new CFO for MiniMed ahead of its intended separation. Price targets have been raised by Morgan Stanley and the stock has been upgraded by Wolfe Research. Investors set a keen eye on the company's pipeline and shares are reportedly underpriced. Furthermore, Medtronic is repeatedly highlighted as a leading medical device stock to purchase, with solid, dependable dividends attracting billionaires, and an AI-powered future sparking investor interest. There are indications of a strong finish to their fiscal year with a dividend increase, positive growth in Q4, and strong cash flow. However, some execution risks exist. Medtronic also announced their intent to separate their Diabetes business, intending to spin it off into a standalone company called MiniMed, adding to future growth potential.
Medtronic Plc MDT News Analytics from Fri, 08 Nov 2024 08:00:00 GMT to Fri, 18 Jul 2025 18:48:00 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -2
